

Evelina Martinenaite

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4641344/publications.pdf>

Version: 2024-02-01

15
papers

400
citations

840119

11
h-index

940134

16
g-index

16
all docs

16
docs citations

16
times ranked

460
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma. <i>Nature Medicine</i> , 2021, 27, 2212-2223. | 15.2 | 88 |
| 2 | CCL22-specific T Cells: Modulating the immunosuppressive tumor microenvironment. <i>Oncolimmunology</i> , 2016, 5, e1238541. | 2.1 | 56 |
| 3 | PD-L1 peptide co-stimulation increases immunogenicity of a dendritic cell-based cancer vaccine. <i>Oncolimmunology</i> , 2016, 5, e1202391. | 2.1 | 33 |
| 4 | The inhibitory checkpoint, PD-L2, is a target for effector T cells: Novel possibilities for immune therapy. <i>Oncolimmunology</i> , 2018, 7, e1390641. | 2.1 | 33 |
| 5 | Arginase 1-Based Immune Modulatory Vaccines Induce Anticancer Immunity and Synergize with Anti-PD-1 Checkpoint Blockade. <i>Cancer Immunology Research</i> , 2021, 9, 1316-1326. | 1.6 | 32 |
| 6 | Frequent adaptive immune responses against arginase-1. <i>Oncolimmunology</i> , 2018, 7, e1404215. | 2.1 | 27 |
| 7 | High frequencies of circulating memory T cells specific for calreticulin exon 9 mutations in healthy individuals. <i>Blood Cancer Journal</i> , 2019, 9, 8. | 2.8 | 27 |
| 8 | The metabolic enzyme arginase-2 is a potential target for novel immune modulatory vaccines. <i>Oncolimmunology</i> , 2020, 9, 1771142. | 2.1 | 18 |
| 9 | Peptide Vaccination Against PD-L1 With IO103 a Novel Immune Modulatory Vaccine in Multiple Myeloma: A Phase I First-in-Human Trial. <i>Frontiers in Immunology</i> , 2020, 11, 595035. | 2.2 | 17 |
| 10 | Arginase-1-based vaccination against the tumor microenvironment: the identification of an optimal T-cell epitope. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1901-1907. | 2.0 | 16 |
| 11 | Spontaneous T-cell responses against Arginase-1 in the chronic myeloproliferative neoplasms relative to disease stage and type of driver mutation. <i>Oncolimmunology</i> , 2018, 7, e1468957. | 2.1 | 15 |
| 12 | Peripheral memory T cells specific for Arginase-1. <i>Cellular and Molecular Immunology</i> , 2019, 16, 718-719. | 4.8 | 13 |
| 13 | Cytotoxic T cells isolated from healthy donors and cancer patients kill TGF β -expressing cancer cells in a TGF β -dependent manner. <i>Cellular and Molecular Immunology</i> , 2021, 18, 415-426. | 4.8 | 10 |
| 14 | Peptide vaccination activating Galectin-3-specific T cells offers a novel means to target Galectin-3-expressing cells in the tumor microenvironment. <i>Oncolimmunology</i> , 2022, 11, 2026020. | 2.1 | 9 |
| 15 | Spontaneous presence of FOXO3-specific T cells in cancer patients. <i>Oncolimmunology</i> , 2014, 3, e953411. | 2.1 | 4 |